# US 2025/0084080 A1 · Crystalline and salt forms of an nlrp3 inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084080 A1
- Document ID: US20250084080A1
- Status: Published application
- Kind: A1
- Application number: 18/882,356
- Filed: 2024-09-11
- Published: 2025-03-13
- Earliest claimed: 2023-09-12
- Assignees: BioAge Labs, Inc.
- Applicants: BioAge Labs, Inc.
- Inventors: Sanjeev Hukmichand Kothari
- Web page: https://patentgrep.com/patent/US20250084080A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure provides crystalline forms of an NLRP3 inhibitor, and methods of making and using these forms.

## Claims

### Claim 1

A crystalline form of 2-ethoxy-3′,5′-difluoro-N-((4-(hydroxymethyl)-1H-pyrazolo[4,3-c]pyridin-7-yl)methyl)-N-methyl-[1,1′-biphenyl]-4-carboxamide, or a pharmaceutically acceptable salt or hydrate thereof.

### Claim 2 (depends on 1)

The crystalline form of claim 1, wherein the crystalline form is a monohydrate.

### Claim 3 (depends on 1)

The crystalline form of claim 1, wherein the crystalline form is an anhydrate.

### Claim 4 (depends on 1)

The crystalline form of claim 1, wherein the crystalline form is a pharmaceutically acceptable salt.

### Claim 5 (depends on 4)

The crystalline form of claim 4, wherein the pharmaceutically acceptable salt is selected from the group consisting of hydrochloric acid salt, phosphoric acid salt, and sodium salt.

### Claim 6 (depends on 3)

The crystalline form of claim 3, wherein the crystalline form is characterized by an XRPD diffractogram having peaks expressed in degrees-2-theta at angles (±0.2 degrees) of 7.2, 20.4, and 20.6.

### Claim 7 (depends on 3)

The crystalline form of claim 3, wherein the crystalline form is characterized by an XRPD diffractogram having peaks expressed in degrees-2-theta at angles (±0.2 degrees) of 7.2, 20.4, 20.6, and 21.6.

### Claim at position 8

8-9. (canceled)

### Claim 10 (depends on 3)

The crystalline form of claim 3 having a DSC thermogram characterized by an endotherm with an onset temperature of 177.3° C.

### Claim 11 (depends on 2)

The crystalline form of claim 2, wherein the crystalline form is characterized by an XRPD diffractogram having peaks expressed in degrees-2-theta at angles (±0.2 degrees) of 6.5, 12.9, and 16.1.

### Claim 12 (depends on 2)

The crystalline form of claim 2, wherein the crystalline form is characterized by an XRPD diffractogram having peaks expressed in degrees-2-theta at angles (±0.2 degrees) of 6.5, 11.2, 12.9, and 16.1.

### Claim 13

(canceled)

### Claim 14 (depends on 2)

The crystalline form of claim 2 having a DSC thermogram characterized by an endotherm with an onset temperature of 139.6° C.

### Claim 15 (depends on 1)

The crystalline form of claim 1, wherein the crystalline form is 2-ethoxy-3′,5′-difluoro-N-((4-(hydroxymethyl)-1H-pyrazolo[4,3-c]pyridin-7-yl)methyl)-N-methyl-[1,1′-biphenyl]-4-carboxamide hydrochloric acid salt.

### Claim 16 (depends on 15)

The crystalline form of claim 15, wherein the crystalline form is characterized by an XRPD diffractogram having peaks expressed in degrees-2-theta at angles (±0.2 degrees) of 12.3, 18.1, and 18.2

### Claim 17 (depends on 15)

The crystalline form of claim 15, wherein the crystalline form is characterized by an XRPD diffractogram having peaks expressed in degrees-2-theta at angles (±0.2 degrees) of 12.3, 12.8, 18.1, 18.2, and 28.7.

### Claim 18

(canceled)

### Claim 19 (depends on 15)

The crystalline form of claim 15 having a DSC thermogram characterized by an endotherm with an onset temperature of 218.3° C.

### Claim 20 (depends on 1)

The crystalline form of claim 1, wherein the crystalline form is 2-ethoxy-3′,5′-difluoro-N-((4-(hydroxymethyl)-1H-pyrazolo[4,3-c]pyridin-7-yl)methyl)-N-methyl-[1,1′-biphenyl]-4-carboxamide phosphoric acid salt.

### Claim 21 (depends on 20)

The crystalline form of claim 20, wherein the crystalline form is characterized by an XRPD diffractogram having peaks expressed in degrees-2-theta at angles (±0.2 degrees) of 3.1, 9.2, and 16.4.

### Claim 22 (depends on 20)

The crystalline form of claim 20, wherein the crystalline form is characterized by an XRPD diffractogram having peaks expressed in degrees-2-theta at angles (±0.2 degrees) of 3.1, 9.2, 11.7, 13.9, 15.4, 16.4, and 24.7.

### Claim 23

(canceled)

### Claim 24 (depends on 20)

The crystalline form of claim 20 having a DSC thermogram characterized by an endotherm with an onset temperature of 223.9° C.

### Claim 25 (depends on 1)

The crystalline form of claim 1, wherein the crystalline form is 2-ethoxy-3′,5′-difluoro-N-((4-(hydroxymethyl)-1H-pyrazolo[4,3-c]pyridin-7-yl)methyl)-N-methyl-[1,1′-biphenyl]-4-carboxamide sodium salt.

### Claim 26 (depends on 25)

The crystalline form of claim 25, wherein the crystalline form is characterized by an XRPD diffractogram having peaks expressed in degrees-2-theta at angles (±0.2 degrees) of 10.3, 21.1, and 25.8.

### Claim 27 (depends on 25)

The crystalline form of claim 25, wherein the crystalline form is characterized by an XRPD diffractogram having peaks expressed in degrees-2-theta at angles (±0.2 degrees) of 10.3, 17.3, 20.6, 21.1, 23.3, and 25.8.

### Claim at position 27

28-29. (canceled)

### Claim 30 (depends on 1)

A pharmaceutical composition comprising the crystalline form of claim 1 and a pharmaceutically acceptable carrier.

### Claim 31 (depends on 1)

A method of inhibiting NLRP3 inflammasome in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the crystalline form of claim 1.

### Claim 32 (depends on 1)

A method of treating inflammation in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the crystalline form of claim 1.

### Claim 33 (depends on 1)

A method of treating inflammaging in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the crystalline form of claim 1.

### Claim 34 (depends on 1)

A method of treating cryopyrin-associated periodic syndrome (CAPS) in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the crystalline form of claim 1.

### Claim 35 (depends on 1)

A method of treating a disease or disorder of the inner ear in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the crystalline form of claim 1.

### Claim 36 (depends on 35)

The method of claim 35, wherein the disease or disorder of the inner ear is selected from the group consisting of hearing loss, hearing impairment, vertigo, Meniere's disease, and tinnitus.
